Drugs / FCN-411
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT03420079 | Aug 2018 → Dec 2020 | lung cancer | Ahon Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2016-04-11 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | Regulatory The new drug of the subsidiary of FOSUN PHARMA obtains the approval in clinical trials fosunpharma.com ↗
On April 6, 2016, Shanghai Fosun Pharmaceutical (Group) Ltd. (“FOSUN PHARMA”) released its announcement that FCN-411 Capsule and its bulk drug (collectively called “this new drug”) manufactured by its subsidiary –Chongqing Fochon Pharmaceuticals, Ltd (“Fochon Pharma”) has obtained the approval of clinical trials from China Food and Drug Administration (CFDA). |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-04-11 | Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. | The new drug of the subsidiary of FOSUN PHARMA obtains the approval in clinical trials fosunpharma.com ↗ |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FCN-411 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03420079 ↗ |
| Action | Inhibit | “FCN-411 is a pan EGFR inhibitor” NCT03420079 ↗ |
| Route | Oral | “FCN-411 will be orally administrated at five sequential dose levels” NCT03420079 ↗ |
| Target | EGFR | “a TKI targeting EGFR, HER2, and HER4” PMID 35248866 ↗ Feb 2022 |